Table 2 Dose metrics for the PTV; median and ranges and statistical outcomes for different energies and arc arrangements for prostate only (PO) plans

HI

1.05

1.04

1.05

1.05

1.05

1.04*

1.05

1.05

1.05

(1.05–1.05)

(1.04–1.05)

(1.04–1.05)

(1.05–1.05)

(1.04–1.05)

(1.04–1.05)

(1.05–1.06)

(1.05–1.06)

(1.05–1.06)

CI

1.18

1.17

1.18

1.17

1.17

1.17

1.18

1.17

1.17

(1.17–1.19)

(1.15–1.19)

(1.15–1.19)

(1.16–1.19)

(1.16–1.19)

(1.16–1.21)

(1.17–1.21)

(1.16–1.20)

(1.16–1.20)

CN

0.93

0.93

0.92

0.92

0.92

0.91

0.91^ɫ

0.91

0.91

(0.92–0.93)

(0.92–0.94)

(0.92–0.93)

(0.91–0.93)

(0.91–0.93)

(0.91–0.92)

(0.91–0.92)

(0.91–0.92)

(0.90–0.91)

R₅₀

3.03

2.94

2.97

3.12

3.16

3.11

3.31^ɫ҂

3.43

3.35

(2.97–3.10)

(2.90–2.99)

(2.92–3.02)

(3.10–3.24)

(3.06–3.23)

(3.02–3.19)

(3.22–3.40)

(3.38–3.48)

(3.22–3.43)

R₂₅

12.00

12.79*

12.64*

13.19

14.72*

14.06

14.24^ɫ҂

16.3*

15.72*

(11.42–12.52)

(12.51–13.91)

(12.04–13.10)

(12.71–13.95)

(13.90–15.37)

(13.43–14.32)

(13.65–15.57)

(15.17–17.68)

(14.75–16.53)

67.2

D_98% (Gy)

35.7

35.8

35.8

35.7

35.7

35.7

35.6

35.6

35.6

(54.6–92.8)

(35.6–36.0)

(35.6–36.1)

(35.6–35.9)

(35.4–36.1)

(35.6–36.1)

(35.4–35.8)

(35.5–35.7)

(35.5–35.8)

(35.3–35.75)

D_2%(Gy)

41.9

41.9

41.9

42.0

41.9*

41.9

42.2^҂

42.2

42.1

(41.9–42.0)

(41.8–41.9)

(41.8–42.0)

(41.9–42.0)

(41.8–41.9)

(41.8–41.9)

(42.0–42.3)

(41.9–42.2)

(41.9–42.3)